ArticleCancer medicine2024

Evaluation of the safety of PD-1/PD-L1 inhibitors for immunotherapy in patients with malignant tumors after COVID-19 infection: A single-center cohort study.

Kaili Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.